Evidence Level:Sensitive: B - Late Trials
Title:
LBA50 - ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)
Excerpt:Treatment-naive pts with classic EGFR mutation (ex19del or L858R) were randomized (1:1)....Prolonged PFS by INV (HR = 0.71, 95% CI 0.53-0.95) was observed...ORR was 77.1% and 73.7% in AG and G arms (p = 0.5572).
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations
Excerpt:...Documented evidence of tumor harboring an activating EGFR mutation (Example 19 del and L858R)...